Biocartis NV: Biocartis and Kite sign agreement for development of Assays supporting Kite’s therapies

Biocartis NV (the ‘Company‘ or ‘Biocartis‘), an innovative molecular diagnostics company (Euronext Brussels: BCART), announced that it has entered into a Master Development and Commercialization Agreement with Kite, a Gilead Company (a pharmaceutical company engaged in the development of innovative cancer cell therapies).

The agreement is aimed at the development of molecular-based assays on Biocartis’ molecular diagnostics Idylla(TM) platform that are supportive to Kite’s therapies. Kite is a subsidiary of Gilead Sciences (GILD) that, as part of its commitment to patients and their physicians, is exploring innovative technologies that may support their care.

Over the past years, immunotherapies – a form of cancer therapy where the power of a patient’s immune system is harnessed to attack tumors – emerged as an important new pillar in cancer treatment. Cell therapies (such as CAR-T therapy or TCRtherapy) are a specific form of immunotherapy where a patient’s own immune cells (i.e. T-cells) are genetically engineered to reprogram these T-cells to specifically attack tumor cells. The speed and ease-of-use of the Idylla(TM) platform could enable regular and rapid monitoring of patients under such cancer cell therapies in a near patient setting, which is expected to help optimize patient management.

The collaboration with Kite is Biocartis’ second assay development partnership in the immunotherapy domain, a fast growing market and one of the key strategic focus areas of the Idylla(TM) assay menu. Cell and checkpoint blockade therapies are expected to cover a wide range of complementary indications in solid and hematological tumors, and may be used depending on the tumor’s immune activity status.

Herman Verrelst, Chief Executive Officer of Biocartis, commented: “We are very pleased to expand our initiatives in the field of immune-oncology through this assay development project with Kite. Being one in the field of anti-cancer cell therapies, they have in-depth knowledge about the current and future diagnostic needs of that therapeutic segment. The collective expertise gained through this partnership further supports one of our long-term strategic goals, aimed at building a menu of high quality and rapid molecular immunotherapy tests on Idylla(TM).” Financial details on the agreement with Kite are not disclosed.


Related presentations

Liked this post?

Share it on your social networks

Photonics Forums Yole CIOE 2020 1140x370